Pacific Biometrics Schedules Year End Conference Call for Monday, September 28, 2009

• Press Release
• Source: Pacific Biometrics, Inc.
• On 8:30 am EDT, Wednesday September 23, 2009

SEATTLE, Sept. 23 /PRNewswire-FirstCall/ -- Pacific Biometrics, Inc. (OTC Bulletin Board: PBME - News), which provides specialty reference laboratory services to support pharmaceutical and laboratory diagnostic manufacturers in the conduct of human clinical research, today announced that it has scheduled an investor conference call for 11:00 a.m. EDT on Monday, September 28, 2009 to review the Company's operating results for the fiscal year ended June 30, 2009. The Company intends to report its operating results after the market closes on Friday, September 25, 2009.

Shareholders and other interested parties may participate in the conference call by dialing 800-860-2442 (international/local participants dial 412-858-4600) and requesting participation in the "Pacific Biometrics, Inc. Conference Call" a few minutes before 11:00 a.m. EDT on September 28, 2009. A replay of the conference call will be available one hour after the call through Monday, October 5, 2009 at 5:00 p.m. EDT by dialing 877-344-7529 (international/local participants dial 412-317-0088) and entering the Conference ID 434163.

About Pacific Biometrics, Inc. (PBI)

Established in 1989, PBI provides specialized central laboratory and contract research services to support pharmaceutical and diagnostic manufacturers conducting human clinical trial research, including expert services in the areas of cardiovascular disease, diabetes, osteoporosis, arthritis, and nutrition. The PBI laboratory is accredited by the College of American Pathologists, New York State, and the Lipid Standardization Program. PBI's clients include many of the world's largest pharmaceutical, biotech, and diagnostic companies.

Pacific Biomarkers, a wholly-owned subsidiary of PBI, focuses specifically on the emerging field of biomarker assay development and testing. Services include validating and performing ligand-binding assays for novel clinical biomarkers, immunogenicity testing, and multiplex testing.

PBI is headquartered in Seattle, Washington, and its common stock trades on the OTC Bulletin Board under the symbol "PBME". For more information about PBI, visit the company's web site at www.pacbio.com.

Buzz up!